YANK!
YOUTUBEJEFF NIPPARD19MOCT 6, 2026

Peptides Are Insane

A biochemist-turned-fitness-creator runs the three categories of peptides through the evidence — and finds one category proven, one promising but thin, and one basically wishful thinking.

Chapters
View source

1 / 5at 12:49 · Yank's paraphrase

BPC-157, the Wolverine peptide all over the internet, has only ever been formally studied in 30 people.

Keeps playing if you go to another page.
Key moments5 highlights from this 19:07 video
0:0019:07

AI Summary

He consults a board-certified physician throughout and fact-checks claims against available research to assess which peptides are genuinely supported by evidence.

A 2018 trial of 2,000 people showed that semaglutide produced 34 lbs of average weight loss versus 6 lbs with a placebo. Newer peptides like tirzepatide and retatrutide show even greater results, with retatrutide achieving 28% weight loss in phase 3 trials.

Yank Summary

What matters, in Yank’s words, each linked to where the source says it.

  1. One in every eight US adults reports using fat loss peptides, and tens of millions are taking them globally.

  2. In a 2018 trial, semaglutide users lost an average of 34 lbs versus 6 lbs in the placebo group over 16 months.

Yank’s 5 cardsYank’s picks from this source. Want something else?

Choose your own Combine with another source
May find some of the same lines.
1 of 5

BPC-157, the Wolverine peptide all over the internet, has only ever been formally studied in 30 people.

Paraphrased from Jeff Nippard on YouTube12:49
Why Yank kept it

The negligible human-trial sample exposes the gap between BPC-157's internet fame and its actual scientific evidence base.

2 of 5

Without weightlifting and proper protein intake, about 40% of the weight lost on a GLP-1 peptide is lean mass.

Paraphrased from Jeff Nippard on YouTube8:19
Why Yank kept it

Muscle loss becomes a near-inevitable consequence when GLP-1 users skip resistance training and adequate protein, framing exercise as non-optional.

3 of 5

Obesity has biological drivers that we can't just necessarily out-discipline or out-willpower — the peptide hits receptors in the brain to eliminate those same biological drivers. Kind of evens the playing field.

Paraphrased from Jeff Nippard on YouTube10:00
Why Yank kept it

A doctor reframes GLP-1 use not as laziness but as correcting a biological disadvantage, directly countering the "shortcut" stigma.

4 of 5

Virtually all compounds marketed as anti-aging solutions follow the same pattern: they probably work in rats, might work in pigs, sometimes work in other primates, and then do basically nothing in humans.

Paraphrased from Jeff Nippard on YouTube17:05
Why Yank kept it

A consistent cross-species failure pattern warns that promising animal data on anti-aging compounds routinely collapses before it reaches humans.

5 of 5

Retatrutide — just through phase 3 clinical trials — caused 28% weight loss; starting at 250 lbs, you'd be expected to lose around 71 pounds in about a year and a half.

Paraphrased from Jeff Nippard on YouTube5:19
Why Yank kept it

A concrete real-world weight example anchors retatrutide's 28% figure, showing why newer multi-receptor peptides are rapidly eclipsing semaglutide.

Keep going with this source

Choose your own lines

Pick the exact words you wanted, at the moment they’re said.

Choose your own →

Create something

Turn this source into a post, a thread or a newsletter, every line checked against it.

See what you can create →

Ask a question

Ask about anything in this video. We’ll try to provide an answer.